文献速递贫血与红细胞疾病

β地中海贫血无效造血条件下的铁代谢

Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.
PubMed 文献 · Blood · 2018-11-06

β地中海贫血(BT)以无效造血(IE)为特征,导致贫血和铁代谢异常。IE是红系祖细胞异常扩增但无法有效生成去核红细胞,引起贫血和缺氧。贫血患者即使无慢性输血也出现铁过载,提示存在调节铁代谢和膳食铁吸收的红系因子。近期研究提示红系细胞分化和存活下降也参与IE,加重贫血;缺氧也可影响并增加铁吸收。理解铁代谢与IE的关系有助于开发新疗法,动物模型显示遗传或药理调控铁代谢或红系细胞分化与存活可改善IE、铁过载和贫血,已有新治疗方法和药物被提出,临床试验正在进行。

要点

  • β地中海贫血的无效造血导致贫血和铁代谢异常,即使无输血也可出现铁过载。
  • 红系细胞分化和存活下降以及缺氧均参与无效造血和铁吸收增加。
  • 动物模型中调控铁代谢或红系细胞分化与存活可改善无效造血、铁过载和贫血。

核心结论

  • 理解铁代谢与无效造血的关系可为β地中海贫血提供重要见解并有助于开发新疗法。
  • 动物模型显示遗传或药理调控铁代谢或红系细胞分化与存活可改善无效造血、铁过载和贫血。
  • 基于这些发现已提出新治疗方法和药物,临床试验正在进行,有望改善β地中海贫血及其他无效造血疾病的红细胞生成、减少铁过载和器官毒性。

研究设计与样本

  • 原文为综述,未报告系统检索范围。

主要发现

  • β地中海贫血以无效造血为特征,导致贫血和铁代谢异常。
  • 无效造血是红系祖细胞异常扩增但无法有效生成去核红细胞,导致贫血和缺氧。
  • β地中海贫血贫血患者即使无慢性输血也出现铁过载,提示存在至少一种调节铁代谢和膳食铁吸收的红系因子。
  • 近期研究提示红系细胞分化和存活下降也参与无效造血,加重β地中海贫血的贫血。
  • 缺氧也可影响并增加铁吸收。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-Thalassemia (BT) is an inherited genetic disorder that is characterized by ineffective erythropoiesis (IE), leading to anemia and abnormal iron metabolism. IE is an abnormal expansion of the number of erythroid progenitor cells with unproductive synthesis of enucleated erythrocytes, leading to anemia and hypoxia. Anemic patients affected by BT suffer from iron overload, even in the absence of chronic blood transfusion, suggesting the presence of ≥1 erythroid factor with the ability to modulate iron metabolism and dietary iron absorption. Recent studies suggest that decreased erythroid cell differentiation and survival also contribute to IE, aggravating the anemia in BT. Furthermore, hypoxia can also affect and increase iron absorption. Understanding the relationship between iron metabolism and IE could provide important insights into the BT condition and help to develop novel treatments. In fact, genetic or pharmacological manipulations of iron metabolism or erythroid cell differentiation and survival have been shown to improve IE, iron overload, and anemia in animal models of BT. Based on those findings, new therapeutic approaches and drugs have been proposed; clinical trials are underway that have the potential to improve erythrocyte production, as well as to reduce the iron overload and organ toxicity in BT and in other disorders characterized by IE.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia. Blood. 2018. PMID: 30401707. doi:10.1182/blood-2018-07-815928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。